Progressive multifocal leukoencephalopathy is a rare but potentially lethal adverse event in natalizumab treated multiple sclerosis patients. We report on a 40-year old Caucasian man with typical relapsing progressive multiple sclerosis, who developed a reversible leukoencephalopathy syndrome after 43 natalizumab infusions mimicking progressive multifocal leukoencephalopathy. To our knowledge, this is the first case of its kind. Our case suggests that awareness ought to be sharpened for reversible leukoencephalopathy syndrome in the follow-up of natalizumab treated multiple sclerosis patients.
WenningWHaghikiaALaubenbergerJ. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med2009; 361: 1075–1080.
6.
BrickelmaierMLugovskoyAKartikeyanR. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother2009; 53: 1840–1849.
7.
SchroderALeeDHHellwigK. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol2010; 67: 1391–1394.
8.
Sanchez-CarteyronAAlarciaRAraJR. Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica. Neurology2010; 74: 1471–1473.
9.
IncecikFHergunerMOAltunbasakS. Reversible posterior encephalopathy syndrome due to intravenous immunoglobulin in a child with Guillain–Barre syndrome. J Pediatr Neurosci2011; 6: 138–140.
